mycosan
בלואייז בע"מ - כלל האוכלוסיה - טיפול ומניעה של פטרת ציפורניים
נוקספיל תרחיף
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
נוקספיל תרחיף
merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
onyster
מדיליין בע"מ - כלל האוכלוסיה - . onychomycosis -טיפול משלים בפטריות בציפורניים, טיפול ב
נוקספיל 100 מג טבליות עמידות בקיבה
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - posaconazole 100 mg - posaconazole
לדגה
rafa laboratories ltd - chlormethine as hydrochloride - ג'ל - chlormethine as hydrochloride 160 mcg/g - chlormethine
ספורנוקס כמוסות
j-c health care ltd - itraconazole 100 mg - capsules - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis . onychomycosis caused by dermatophytes and/or yeasts. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.
איטרנול
rafa laboratories ltd - itraconazole - קפסולות - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.
מיקוסטר % 8 לק לציפורניים
perrigo israel agencies ltd - ciclopirox - לק - ciclopirox 8 %w/w - ciclopirox
מיקוסטר % 8 לק לציפורניים
perrigo israel agencies ltd - ciclopirox - לק - ciclopirox 8 %w/w - ciclopirox